|
Clinical Trials Software Markets, 2035
Wednesday, April 27, 2022
DUBLIN, April 19, 2022 /PRNewswire/ -- The "Clinical Trials Software Market: Distribution by Type of Deployment, Type of Delivery, Features of software and Geographical Regions, Industry Trends and Global Forecasts, 2022-2035" report has been added to ResearchAndMarkets.com's offering.
https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
The Clinical Trials Software Market, 2022-2035 report features an extensive study of the current market landscape and future opportunity for the players involved in the development of clinical trials software. The study presents an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain, across different geographies.
One of the key objectives of the report was to estimate the future growth potential of clinical trials software market, over the coming decade. We have provided informed estimates on the financial evolution of the market for the period 2021-2035. In order to account for uncertainties and to add robustness to our model, we have provided three market forecast scenarios, portraying the conservative, base and optimistic tracks of the anticipated industry's growth.
It is a well-known fact that clinical trials form an integral part of the overall drug development process, enabling innovators to assess safety and efficacy of their drug candidates / devices. These studies account for around 50% of the total time and capital invested in the development process.
However, the conduct of trials is often fraught with several challenges, including scientific and operational complexity, concerns associated with recruitment and retention of suitable patients, issues related to data handling and increasingly stringent regulatory guidelines. In fact, the failure of a clinical trial can impose an enormous financial burden on sponsors, estimated to be in the range of USD 800 million (in case of therapies with limited applications) to USD 1.4 billion (for a drug that is anticipated to be a blockbuster). Further, during the COVID-19 pandemic, the conduct of clinical trials has become increasingly difficult.
In order to address these challenges, players engaged in the pharmaceutical industry have leveraged novel and advanced digital health technologies, such as mobile devices, advanced applications, remote monitoring devices, telemedicine, and online social interaction platforms for virtual conduct of clinical trials.
Various clinical trials software, including EDC, eCOA/ePRO, and eConsent integrated clinical study automation software, are also being recruited to collect data at each stage of the trial, improve trial participant recruitment and retention, provide eConsent, measure real-time clinical outcomes, and track adverse events in real-time.
Virtual clinical trials software solutions have the potential to induce substantial digital changes in clinical research methodology, resulting in a more patient-centric, cost-effective and easy to manage approach. They enable the participants to participate from the comfort of their own homes rather than traveling to a study location, which enhance participant engagement and retention.
At present, several companies are engaged in the development of clinical trials software, which allow drug developers to enhance the quality of their clinical products and reduce the time to get a product to market. The market has witnessed substantial partnership activity over the last few years.
The activity in this segment has also attracted the attention of both private and public sector investors / investment funds, which have extended financial support to the initiatives of capable developer companies. Driven by the substantial progress in this domain, encouraging virtual clinical trial results, and ongoing technological advancement, the clinical trials software market is anticipated to grow at a commendable pace in the mid to long term.
Amongst other elements, the report includes:
-- An overview of clinical trials software market, featuring a detailed
market landscape analysis based on several relevant parameters, such as
type of deployment (on-cloud, on-premises), type of delivery (web-based,
remote monitoring), type of end-user (pharmaceuticals, biotechnology,
CROs), features of software (EDC, eCOA/ePRO, eConsent), trial design
(decentralized, site-based, hybrid, randomized, case control, cohort),
type of technology (IVRS, IWRS). It also provides insights on developer
landscape along with the analysis based on year of establishment,
company size, location of headquarters.
-- An insightful competitiveness analysis of clinical trials software
developers, taking into consideration the supplier strength (based on
expertise of the manufacturer), product portfolio strength and service
applicability.
-- An analysis of the partnerships that have been inked by various
stakeholders engaged in the development of clinical trials software,
during the period 2016-2021, covering service agreements, research
agreements, licensing agreements, product development, product
integration, product utilization and other types of partnership deals.
-- An analysis of the mergers and acquisitions of various stakeholders
engaged in the development of clinical trials software, during the
period 2016-2021.
-- An analysis of the investments made at various stages of development of
clinical trials software companies engaged in this field, covering
instances of seed funding, venture capital funding, debt financing,
grant and other equity.
-- Tabulated profiles of the key players providing clinical trials
software. Each profile includes an overview of the company, product
portfolio, recent developments, and an informed future outlook.
Key Questions Answered
-- Who are the leading players engaged in the development of clinical
trials software solutions?
-- Which region(s) will occupy the maximum market share in clinical trials
software domain?
-- Who are the key venture capitalists / strategic investors funding the
clinical trials software development initiatives?
-- Which partnership models are commonly adopted by stakeholders engaged in
the development of clinical trials software solutions?
-- Which factors are likely to influence the evolution of this market?
-- How is the current and future market opportunity likely to be
distributed across key market segments?
Key Topics Covered:
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Existing Constraints in Clinical Research
3.2.1. Increasing Trial Costs and Complexity
3.2.2. Evolving Regulatory Standards
3.2.3. Patient Recruitment and Retention-Related Challenges
3.2.4. Inefficient Data Handling
3.3. Virtual Clinical Trials
3.3.1. Electronic Data Capture Solutions
3.3.2. Electronic Clinical Outcome Assessment and Electronic Patient Reported Outcome Solutions (eCOA / ePRO)
3.3.3. Electronic Consent Solutions
3.4. Opportunities and challenges associated with Virtual Clinical Trials Management
3.5 Future Perspectives
4. MARKET LANDSCAPE: CLINICAL TRIALS SOFTWARE MARKET
4.1. Chapter Overview
4.2. Clinical Trials Software Market: List of Products
4.2.1. Analysis by Type of Deployment
4.2.2. Analysis by Type of Delivery
4.2.3. Analysis by End-User
4.2.4. Analysis by Features of Software
4.2.5. Analysis by Trial Design
4.2.6. Analysis by Type of Technology
4.3. Clinical Trials Software Market: Developer Landscape
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4.3.3. Analysis by Geography
5. CLINICAL TRIALS SOFTWARE DEVELOPERS IN NORTH AMERICA: COMPANY PROFILES
5.1. Chapter Overview
5.2. Advarra
5.2.1. Company Overview
5.2.2. Product Portfolio: Clinical Trials Software
5.2.3. Recent Developments and Future Outlook
5.3. Arisglobal
5.4. AssistRx
5.5. Clario
5.6. IBM
5.7. IQVIA
5.8. Medidata
5.9. Oracle
5.10. Signant Health
5.11. Veeva
6. CLINICAL TRIALS SOFTWARE DEVELOPERS IN EUROPE: COMPANY PROFILES
6.1. Chapter overview
6.2. Calyx
7. COMPANY COMPETITIVENESS ANALYSIS
7.1. Chapter Overview
7.2. Key Parameters and Methodology
7.3. Competitiveness Analysis: Companies providing clinical trials software developers
7.4. Competitiveness Analysis: Companies providing clinical trials software in North America
7.5. Competitiveness Analysis: Companies providing clinical trials software in Europe
7.6. Competitiveness Analysis: Companies providing clinical trials software in Asia-Pacific
8. PARTNERSHIPS AND COLLABORATIONS
8.1. Chapter Overview
8.2. Partnership Models
8.3. Clinical Trials Software Market: Partnerships and Collaborations
8.4. Geographical Analysis
8.5. Most Active Players: Analysis by Number of Partnerships
9. MERGERS AND ACQUISITIONS
9.1. Chapter Overview
9.2. Mergers and Acquisitions Models
9.3. Clinical Trials Software Market: Mergers and Acquisitions
9.4. Analysis by Geographical Activity
9.5. Most Active Players: Analysis by Number of Instances Acquisitions and Mergers
10. FUNDING AND INVESTMENT ANALYSIS
10.1. Chapter Overview
10.2. Types of Funding Instances
10.3. Clinical Trials Software Market: Recent Funding Instances
10.4. Most Active Players: Analysis by Number of Funding Instances
10.5. Regional Analysis by Amount Invested
10.6. Concluding Remarks
11. MARKET FORECAST AND OPPORTUNITY ANALYSIS
11.1. Chapter Overview
11.2. Forecast Methodology and Key Assumptions
11.3. Global Clinical Trials Software Market, 2021-2035
12. CONCLUSION
12.1. Chapter Overview
13. Appendix 1: Tabulated Data
14. Appendix 2: List of Companies and Organizations
For more information about this report visit https://www.researchandmarkets.com/r/t7pppv
Media Contact:
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
View original content:https://www.prnewswire.com/news-releases/clinical-trials-software-markets-2035-301527748.html
SOURCE Research and Markets
|
|
|
|
|
|
 |
Weekly Recap: 11 Tech Press Releases You Need to See | Jan 22, 2026
|
|
Sup AI Sets New Benchmark Record with 52.15% on Humanity's Last Exam | Jan 22, 2026
|
|
Trigent Partners with WeWork India to Expand its GCC Footprint | Jan 22, 2026
|
|
Skunk Works® and XTEND Expand Joint All Domain Command and Control for Advanced Mission Execution | Jan 22, 2026
|
|
DEADLINE ANNOUNCED FOR 2026 NEW TOP-LEVEL DOMAIN APPLICATIONS | Jan 22, 2026
|
|
Altair HyperWorks 2026 Delivers Design and Simulation at Scale with AI | Jan 22, 2026
|
|
Glasswall Brings Defense-Level File Sanitization to Every Government Agency and Business Using Microsoft 365 | Jan 22, 2026
|
|
Exia Labs Brings Keystone to the U.S. Navy via DIU's Blue Object Management Challenge | Jan 22, 2026
|
|
Marketing Evolution Announces New Investment Led by Insight Partners to Power AI-Ready Marketing Data for the Agentic Era | Jan 22, 2026
|
|
Genpact Named a Leader in ISG Provider Lens(TM) 2025 for Insurance GCCs and Agentic AI Services | Jan 22, 2026
|
|
|
|
